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ABSTRACT
Impaired hepatic bile acid export may contribute to development
of cholestatic drug-induced liver injury (DILI). The multidrug
resistance-associated proteins (MRP) 3 and 4 are postulated to
be compensatory hepatic basolateral bile acid efflux transporters
when biliary excretion by the bile salt export pump (BSEP) is
impaired. BSEP inhibition is a risk factor for cholestatic DILI. This
study aimed to characterize the relationship between MRP3,
MRP4, and BSEP inhibition and cholestatic potential of drugs.
The inhibitory effect of 88 drugs (100 mM) on MRP3- and MRP4-
mediated substrate transport was measured in membrane vesicles.
Drugs selected for investigation included 50 BSEP non-inhibitors (24
non-cholestatic; 26 cholestatic) and 38 BSEP inhibitors (16 non-
cholestatic; 22 cholestatic). MRP4 inhibition was associated with an
increased risk of cholestatic potential among BSEP non-inhibitors. In
this group, for each 1% increase in MRP4 inhibition, the odds of the
drug being cholestatic increased by 3.1%. Using an inhibition cutoff
of 21%, which predicted a 50% chance of cholestasis, 62% of
cholestatic drugs inhibited MRP4 (P < 0.05); in contrast, only 17%
of non-cholestatic drugs were MRP4 inhibitors. Among BSEP in-
hibitors, MRP4 inhibition did not provide additional predictive
value of cholestatic potential; almost all BSEP inhibitors were also
MRP4 inhibitors. Inclusion of pharmacokinetic predictor variables (e.g.,
maximal unbound concentration in plasma) in addition to percent
MRP4 inhibition in logistic regression models did not improve cho-
lestasis prediction. Association of cholestasis with percent MRP3
inhibition was not statistically significant, regardless of BSEP-inhibition
status. Inhibition of MRP4, in addition to BSEP, may be a risk factor
for the development of cholestatic DILI.
Introduction
Drug-induced liver injury (DILI) is a frequent and serious side
effect of drug therapy and a major concern in drug discovery and
clinical development. DILI is one of the leading causes of acute liver
failure and was the most frequent reason for withdrawal of approved
drugs from the US market between 1975 and 2000 (Lasser et al., 2002;
Lee, 2003).
The term DILI describes different manifestations of liver toxicity
following drug exposure ranging from asymptomatic elevation of
liver enzymes to hepatic failure. Cholestatic and hepatocellular liver
injury are the two major types of DILI. Unfortunately, at present, the
pathophysiological mechanisms of hepatotoxicity are not well defined.
Hypothesized mechanisms include apoptosis of hepatocytes, immune-
mediated mechanisms, mitochondrial disruption, and bile duct injury,
as well as inhibition of transport proteins. One proposed mechanism of
cholestatic DILI is inhibition of bile acid transport, leading to necrotic
and/or apoptotic cell death due to increased hepatocellular concen-
trations of bile acids (Hofmann, 1999; Wagner et al., 2009).
Hepatocytes are polarized cells that have specialized transport sys-
tems in the canalicular/apical and sinusoidal/basolateral membrane to
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maintain hepatic bile acid homeostasis. Under physiologic conditions,
bile acids are excreted across the canalicular membrane into bile, where
they form micelles with other bile components such as phospholipids or
cholesterol. The bile salt export pump (BSEP), an ATP-dependent
export protein located in the canalicular membrane, transports bile acids
from the hepatocyte into bile (Noe et al., 2002). Because of BSEP’s
central role in the hepatic excretion of bile acids, functional impairment
of BSEP has been hypothesized to play a role in the development of
liver injury. For example, patients with mutations in the ABCB11/BSEP
gene that result in reduced expression levels or function of BSEP [e.g.,
progressive familial intrahepatic cholestasis type II] exhibit reduced bile
acid excretion compared with normal patients, and rapidly develop liver
injury due to hepatocellular accumulation of toxic bile acids (Jansen
et al., 1999; Jansen and Muller, 2000; Perez and Briz, 2009). Several
hepatotoxic drugs, including troglitazone, erythromycin, and bosentan,
inhibit BSEP function in in vitro systems such as sandwich-cultured
hepatocytes or BSEP membrane vesicle assays (Stieger et al., 2000;
Fattinger et al., 2001; Kostrubsky et al., 2003). Recently, several large
studies systematically investigated the relationship between DILI and
BSEP inhibition using BSEP membrane vesicles (Morgan et al., 2010;
Dawson et al., 2012; Morgan et al., 2013). These studies provided
compelling evidence for an association between BSEP inhibition and
hepatotoxicity. Furthermore, drugs with mixed hepatocellular and cho-
lestatic liver injury exhibited increased potency to inhibit BSEP compared
with drugs that only exhibited hepatocellular injury, or drugs that were not
hepatotoxic (Dawson et al., 2012). However, the studies by Morgan et al.
and Dawson et al. also clearly demonstrated that not all cholestatic drugs
are BSEP inhibitors, suggesting that additional independent factors may
be involved in the development of cholestatic liver injury.
In addition to apically localized BSEP, the basolateral multidrug
resistance-associated proteins (MRP) 3 (ABCC3) and MRP4 (ABCC4)
are involved in ATP-dependent bile acid export (Zeng et al., 2000; Rius
et al., 2003; Zelcer et al., 2003b). Under normal physiologic conditions,
the hepatic expression of MRP3 and MRP4 is low, whereas upre-
gulation under cholestatic conditions (e.g., inhibition of BSEP, genetic
BSEP variants) has been observed (Gradhand et al., 2008; Chai et al.,
2012). Therefore, these basolateral proteins are hypothesized to provide
a compensatory backup system for bile acid efflux from the hepatocyte
into sinusoidal blood when the normal vectorial transport of bile acids
from the hepatocyte into bile is compromised (Scheffer et al., 2002;
Teng and Piquette-Miller, 2007; Gradhand et al., 2008; Chai et al.,
2012). The contribution of Mrp4 to bile acid homeostasis and its role in
the development of liver injury are highlighted by elevated liver
concentrations of specific bile acids and increased liver toxicity in
bile duct–ligated Mrp4 knockout compared with wild-type mice
(Mennone et al., 2006).
As previous studies demonstrated, the prediction of cholestatic potential
of a compound based on BSEP inhibitor status alone is characterized by
a high incidence of false negatives (i.e., cholestatic compounds that do
not inhibit BSEP) and false positives (i.e., BSEP inhibitors that are non-
cholestatic). In the present study, 88 non-cholestatic as well as cho-
lestatic drugs classified as BSEP inhibitors or non-inhibitors, and the
relationship between inhibition of MRP3, MRP4, and the risk of
cholestatic DILI, were investigated. This study was designed to test the
hypothesis that the prediction of cholestatic DILI could be improved by
information about the compound’s ability to inhibit the basolateral bile
acid transporters, MRP3 and MRP4, in addition to BSEP.
Materials and Methods
Materials. [3H]-Dehydroepiandrosterone-sulfate (DHEAS; 63 Ci/mmol),
[3H]-estradiol-17b-glucuronide (E217G; 50.3 Ci/mmol), and Microscint-O
liquid scintillation fluid were purchased from Perkin Elmer Life and Analytical
Sciences (Waltham, MA). Compounds were purchased from Sigma-Aldrich
(St. Louis, MO), unless otherwise indicated. Cell culture supplies were obtained
from Gibco (Life Technologies, Grand Island, NY). Dimethylsulfoxide (DMSO)
was purchased from Fisher Scientific (Fairlawn, NJ).
Compound Selection. A total of 88 structurally diverse compounds from
different therapeutic groups was selected to study MRP3 and MRP4 inhibition.
Compounds were classified as BSEP non-inhibitors or inhibitors, and then
cross-classified as non-cholestatic or cholestatic. Cholestatic classification
relied on Thompson’s Micromedex DRUGDEX index (available at http://www.
micromedex.com/products/drugdex/) and the Lexicomp database (available at
http://www.lexi.com/) as well as literature information. Compounds were classified
as cholestatic if cholestatic liver injury or case reports of cholestasis had been
reported. Compounds classified as non-cholestatic comprised a mixed population
that included drugs with no potential for liver injury or drugs for which the liver
damage was hepatocellular with no reports of cholestasis. The compounds were
classified further as BSEP inhibitors. Using receiver operator characteristic curve
analysis of 85 compounds, Dawson et al. (2012) reported 300 mM as the optimal
IC50 cutoff to separate drugs that exhibited cholestatic/mixed liver injury from
drugs that caused hepatocellular injury or no DILI. However, because the max-
imal IC50 value reported for taurocholate transport in BSEP membrane vesicles by
Morgan et al. (2010) was 135 mM, this lower value was chosen for classification of
BSEP inhibitors in the present study to reduce the constraint of substrate selection
(Morgan et al., 2010; Dawson et al., 2012). Information on hepatic metabolism, the
primary routes of excretion, and clinical parameters were retrieved from Thompson’s
Micromedex DRUGDEX index, Lexicomp database, the AHFS Drug Information
textbook (American Society of Health-System Pharmacists, 2012), and PubMed.
Cell Culture and Overexpression of MRP3 and MRP4. Human MRP3
plasmid (pcDNA3.12-MRP3) and MRP4 plasmid (pcDNA3.1+-MRP4) were
kindly provided by Dr. Susan Cole (Queen’s University, Kingston, Canada) and
Dr. Dietrich Keppler (German Cancer Research Center, Heidelberg, Germany),
respectively. Human embryonic kidney 293T (HEK293T) cells were cultured in
Dulbecco’s modified essential medium supplemented with 10% fetal bovine serum
in a humidified incubator (5% CO2, 37°C). For MRP4, a stable transfected cell line
was developed by transfecting HEK293T cells with the plasmid pcDNA3.1+-MRP4
using the Fugene-6 transfection kit (Roche Diagnostics, Mannheim, Germany).
Single colonies were selected by treatment with hygromycin (150 mg/ml) and char-
acterized for MRP4 protein expression using immunofluorescence and immunoblot
analysis. Control cells using the vector pcDNA3.1+ were established using the same
method. For membrane vesicle preparation, HEK293T-MRP4–overexpressing cells
and the control cell line were trypsinated and centrifuged at 900g for 5 minutes at
4°C. The cell pellet was washed twice in 10 ml of Tris-sucrose buffer (TSB; 250 mM
sucrose/50 mM Tris, pH 7.4) containing 0.25 mM CaCl2 using centrifugation
conditions described above. The final cell pellet was overlaid with 10 ml of TSB
containing 0.25 mM CaCl2 and protease inhibitors (complete mini EDTA-free;
Roche Diagnostics), snap frozen in liquid nitrogen, and stored at 280°C.
For MRP3, transient transfection of HEK293T cells with X-tremeGENE 9
DNA transfection reagent (Roche Diagnostics) was performed according to the
manufacturer’s instructions using a ratio of 3:1 of X-tremeGENE 9 and
pcDNA2-MRP3 plasmid DNA. Seventy-two hours after transfection, the cells
were harvested as described above for MRP4. Nontransfected cells were used
to generate control membrane vesicles for the MRP3 assay.
Membrane Vesicle Preparation. Membrane vesicles were prepared, as
described previously (Ghibellini et al., 2008). Briefly, frozen cell pellets were
thawed, resuspended in TSB, and exploded by N2 cavitation (300 psi, 5
minutes). After addition of EDTA (final concentration: 1 mM), the suspension
was centrifuged (800g, 10 minutes, 4°C) and the supernatant was collected. The
pellet was resuspended in TSB with 0.5 mM EDTA (final concentration) and
centrifuged (800g, 10 minutes, 4°C). The resulting supernatants were overlaid
over 35% (w/w) sucrose/50 mM Tris buffer (pH 7.4) in a high-speed centrifuge
tube. After centrifugation (100,000g, 90 minutes, 4°C), the interphase was collected
and added to a new high-speed centrifuge tube with 25 mM sucrose/50 mM Tris
buffer (pH 7.4). After additional centrifugation (100,000g, 45 minutes, 4°C), the
pellet was resuspended in 1 ml of TSB. The suspension was added to a high-speed
centrifuge tube and centrifuged (100,000g, 20 minutes, 4°C). Thereafter, the
supernatant was discarded and the pellet was resuspended in TSB to a concentration
of ;3–6 mg/ml. Subsequently, the suspension was homogenized using a 27-gauge
needle (15 strokes). The membrane vesicle suspension was divided into aliquots,
snap frozen in liquid nitrogen, and stored at 280°C.
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Membrane Vesicle Assay. Compound screening for interaction with MRP3
and MRP4 was performed using a high-throughput method (Supplemental Fig.
1). Briefly, membrane vesicles (10 mg) were incubated at 37°C with test
compound (100 mM) or DMSO (vehicle control) in TSB containing MgCl2
(10 mM), creatine phosphate (10 mM), creatine kinase (100 mg/ml), ATP
(4 mM), and [3H]-E217G (0.4 mCi/ml; 10 mM) for MRP3, or [
3H]-DHEAS
(0.7 mCi/ml; 2 mM) for MRP4, in a final volume of 50 ml. The test compound
stock solutions were prepared at 10 mM in 100% DMSO, resulting in a final
concentration of 1% DMSO. For control reactions, ATP was replaced with
4 mM AMP. MK571 (100 mM) was used as a positive control for inhibition.
Vehicle control and positive control reactions were performed in triplicate on
each 96-well plate. Incubations with test compounds were performed in a
minimum of three separate experiments. After incubation for 10 minutes
(MRP3) or 3.5 minutes (MRP4), the reaction was stopped by addition of 150 ml
of ice-cold TSB and the entire sample was immediately filtered through GF/B
Unifilters (Perkin Elmer; presoaked in 3 mM reduced glutathione/10 mM
dithiothreitol in TSB overnight). Under aspiration, the wells were washed three
times with ice-cold TSB using a vacuum filtration system. Microscint-20 (75
ml) was added to each well before counting radioactivity using a TopCount
scintillation counter (Perkin Elmer, Waltham, MA). The ATP-dependent
uptake of substrate was calculated by subtracting substrate uptake in the
presence of AMP from substrate uptake in the presence of ATP. MRP-dependent
substrate transport was calculated by subtracting ATP-dependent substrate accu-
mulation in control or nontransfected membrane vesicles from substrate uptake in
membrane vesicles prepared from MRP-transfected cells. Data are presented as
percentage of vehicle-treated membrane vesicles (mean 6 S.D.; n = 3). Kinetic
parameters for E217G (MRP3) and DHEAS (MRP4) transport were estimated
using the Michaelis-Menten equation. IC50 values were estimated by nonlinear
regression (Prism 5.0; GraphPad Software Inc., La Jolla, CA).
Statistical Analysis Strategy. Consistent with the study design, the primary
results were obtained via a BSEP-stratified case-control analysis to evaluate the
association between cholestasis and inhibition of MRP3 or MRP4. Cases were
defined as compounds with a documented history of cholestatic DILI. Logistic
regression models for cholestatic status were used to evaluate the predictive value
of MRP3 inhibition and, separately, of MRP4 inhibition. Because BSEP inhibition
is a known susceptibility factor for DILI (Morgan et al., 2010; Dawson et al.,
2012), the logistic regression analyses were performed separately for BSEP non-
inhibitors and BSEP inhibitors. The fitted models also were used to estimate odds
ratios (with 95% confidence intervals) representing the increase in risk of cho-
lestasis per unit increase in MRP3 or MRP4 percent inhibition. A corresponding
null hypothesis, no association between cholestasis and MRP3 (or MRP4)
inhibition, was tested using a Wald x2 test procedure of size a = 0.05.
Additional analyses were performed to evaluate the robustness of these
primary results to reasonable perturbations of assumptions and statistical
methods used. For example, 1) the association between MRP3 (or MRP4)
inhibition and cholestasis was evaluated by comparing non-cholestatic with
cholestatic compounds in regard to median MRP3 (or MRP4) inhibition, fol-
lowed by a Wilcoxon rank sum test procedure, and 2) association of cholestasis
with MRP inhibition was evaluated in logistic regression models using
dichotomized versions of MRP3 and MRP4 percent inhibition.
Additional analyses were conducted to generate new hypotheses to define MRP
dichotomizations and other statistical models that might best predict cholestasis. For
example, based on the primary logistic regression models, cutoffs defining MRP3
and MRP4 dichotomizations of interest included the following: 1) the MRP3 or
MRP4 inhibition value that predicted a 50% chance of cholestasis, and 2) cutoffs
suggested by receiver operating characteristic curve analysis. Logistic regression
models of interest included predictors such as MRP4 percent inhibition, maximal
unbound concentration in plasma (Cmax,u), maximum daily dose (MDD), average
daily dose, protein binding, route of excretion, and extent of metabolism. In all
cases, statistical computations were performed using SAS (SAS version 9.3; SAS
Institute, Cary, NC) or Prism 5.0 (GraphPad Software Inc.).
Results
Characterization of Membrane Vesicles Expressing MRP3 and
MRP4. Membrane vesicles strongly expressed MRP3 and MRP4, as
measured by Western blot analysis, compared with membrane vesicles
from the non- or control-transfected parental cell line (Fig. 1). ATP-
dependent uptake of 10 mM E217G (MRP3) and 2 mM DHEAS (MRP4)
was approximately linear up to 15 and 10 minutes, respectively. MRP3-
dependent E217G and MRP4-dependent DHEAS transport were con-
centration dependent and well described by Michaelis-Menten kinetics
(Fig. 1). Km values of 9.16 0.9 mM and 3.56 0.5 mM, and Vmax values
of 116 6 2.7 pmol/min/mg protein and 387 6 18 pmol/min/mg protein
for MRP3 and MRP4, respectively, were estimated by nonlinear least-
square regression.
Inhibition of MRP Transport Activity in Membrane Vesicles by
the Test Compounds. Eighty-eight drugs including 50 BSEP non-
inhibitors (24 non-cholestatic, 26 cholestatic) and 38 BSEP inhibitors
(16 non-cholestatic, 22 cholestatic) (Morgan et al., 2010; Dawson
et al., 2012) were screened for inhibition of MRP3- and MRP4-
mediated substrate transport in membrane vesicles. A wide range of
inhibition values was observed in all groups. For MRP3, pioglitazone,
rosiglitazone, ticlopidine, and praziquantel stimulated, rather than in-
hibited, substrate transport by more than 40% (Fig. 2; Table 1). Cor-
relation between MRP3 and MRP4 percent inhibition was observed
among BSEP non-inhibitors and BSEP inhibitors (Spearman’s r =
0.53 and r = 0.40, respectively; both P values #0.05; data not shown).
The box-and-whisker plots (Fig. 2, right panel) show that among
BSEP non-inhibitors, median MRP4 (and MRP3) percent inhibition
was higher for cholestatic compounds compared with non-cholestatic
compounds, whereas similar median percent MRP4 (and MRP3) inhi-
bition was observed for non-cholestatic and cholestatic compounds
among BSEP inhibitors (Fig. 2).
BSEP Non-Inhibitors: Association of Cholestasis with MRP
Inhibition. Current in vitro BSEP inhibition assays aim to predict
cholestasis at an early stage in drug development. The observed high
false-negative rate poses a significant attrition risk due to the unpredicted
cholestatic potential. To test the hypothesis that information on MRP3/
MRP4 inhibition can reduce this false-negative rate, analyses were
performed for drugs that do not inhibit BSEP.
Among the 50 BSEP non-inhibitors, a statistically significant as-
sociation was detected between cholestasis and percent MRP4
inhibition using logistic regression analysis (Fig. 3). The odds that
a drug was cholestatic increased by 3.1% (95% confidence interval:
0.7% to 5.6%) for each 1% increase in MRP4 inhibition. In other
words, as MRP4 percent inhibition increased from 0% to 21% to
100%, the probability that a drug is cholestatic increased from 35% to
50% to 92%. Using MRP4 percent inhibition $21%, which predicted
a 50% chance of cholestasis, as a criterion for dichotomization
(cutoff), 20 of the 50 BSEP non-inhibitors were classified as MRP4
inhibitors for purposes of further descriptive and exploratory anal-
yses. As expected from the primary logistic regression analysis, this
classification was predictive of cholestatic potential using a x2 test
(Table 2). Using this dichotomized approach, in the group of BSEP
non-inhibitors, 62% of the cholestatic drugs (16 of 26) were MRP4
inhibitors, whereas only 17% of the non-cholestatic drugs (4 of 24)
were MRP4 inhibitors (Table 2). Furthermore, among BSEP non-
inhibitors, 16 of 20 (80%) MRP4 inhibitors were correctly classified
as cholestatic; however, 10 of 26 (38%) cholestatic drugs were not
MRP4 inhibitors.
A cutoff value of 19% predicted a 50% chance of cholestasis for
MRP3, using the method described for MRP4. However, the primary
logistic regression analysis of an association between percent MRP3
inhibition and cholestatic potential was not statistically significant.
Furthermore, MRP3 and MRP4 inhibition were strongly correlated.
Therefore, additional exploratory analyses described below with
clinical and pharmacokinetic parameters were performed only for
MRP4, but not MRP3, inhibitor status (using a cutoff of 21%).
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BSEP Inhibitors: Association of Cholestasis with MRP Inhibition.
As previously noted, some drugs that inhibit BSEP in vitro are not
cholestatic in vivo (Dawson et al., 2012). Categorizing compounds as
potentially cholestatic based on BSEP inhibition status alone may result
in the erroneous exclusion of drug candidates in the drug development
process. In the present study, BSEP inhibitors were analyzed further to
address whether MRP3 or MRP4 inhibition could help discriminate
between cholestatic and non-cholestatic drugs in this group. Among the
38 BSEP inhibitors, association of cholestasis with percent inhibition of
MRP3- or MRP4-mediated transport was not detected in the primary
logistic regression analysis (Fig. 3). For further analyses, MRP4 percent
inhibition was dichotomized using the same cutoff values that had been
developed for BSEP non-inhibitors (Table 2; Fig. 3). Using this approach,
almost all BSEP inhibitors also were classified as MRP4 inhibitors. There
was a slight enrichment of MRP4 inhibitors among cholestatic com-
pounds (95%, 21 of 22) compared with non-cholestatic drugs (75%, 12 of
16); however, this did not reach statistical significance.
Association of Clinical Parameters with BSEP and MRP4
Inhibition. Our data demonstrate that MRP4 inhibition is able to
predict cholestatic potential among compounds that are BSEP non-
inhibitors; however, 38% of the cholestatic drugs in this group are not
inhibitors of MRP4. Furthermore, we demonstrated that, even with
information on the percent of MRP4 inhibition (and MRP4 inhibitor
status), we are not able to discriminate between cholestatic and non-
cholestatic drugs among BSEP inhibitors. These findings suggest that,
in addition to BSEP and MRP4, other factors need to be considered to
improve the prediction of liver injury. In an attempt to identify con-
tributing elements, pharmacokinetic data were collected as described
in Materials and Methods (Supplemental Table 1). Robust statistical
analyses suggest that there is little or no association between the type
of DILI and extent of metabolism or route of excretion, regardless of
the BSEP inhibitor status (Supplemental Tables 2 and 3 with odds
ratios).
Furthermore, as observed previously by Dawson et al. (Dawson
et al., 2012), there was no statistically significant difference between
non-cholestatic and cholestatic compounds with regard to the Cmax,u or
the MDD (Fig. 4, A and D). However, cholestatic BSEP non-inhibitors
were characterized by higher median Cmax,u values compared with
cholestatic BSEP inhibitors and non-cholestatic drugs. Similarly, higher
median Cmax,u values were observed in cholestatic MRP4 non-inhibitors
compared with both cholestatic and non-cholestatic MRP4 inhibitors
(P , 0.05) (Fig. 4; Supplemental Table 4). Cholestatic MRP4 non-
inhibitors had a higher median MDD compared with cholestatic MRP4
inhibitors and non-cholestatic MRP4 non-inhibitors. However, inclusion
of Cmax,u, MDD, and average daily dose, protein binding, route of
excretion, and extent of metabolism as predictor variables in addition to
MRP4 percent inhibition in logistic regression equations did not
improve the prediction of cholestasis.
Discussion
Inhibition of BSEP, which transports bile acids from the hepatocyte
into bile, correlates with the risk of cholestatic DILI in humans
(Morgan et al., 2010; Dawson et al., 2012). However, comprehensive
studies indicate that not all cholestatic compounds are BSEP inhi-
bitors, and not all BSEP inhibitors cause cholestasis, suggesting that
factors in addition to BSEP inhibition are involved in the development
of cholestatic liver injury. The present study examined the relationship
Fig. 1. Characterization of MRP3 and MRP4 membrane vesicles and substrate transport. (A) Time course of ATP-dependent substrate uptake. ATP-dependent uptake of
[3H]-E217G (10 mM; MRP3, left panel) or [
3H]-DHEAS (2 mM; MRP4, right panel) in plasma membrane vesicles (10 and 5 mg, respectively) prepared from control cells (d)
or MRP3- or MRP4-overexpressing cells (s) was measured, as described in Materials and Methods. Insert, Western blot of MRP3 and MRP4, respectively, in membrane
vesicles prepared from MRP-overexpressing or control cells. (B) Concentration-dependent transport. The rates of MRP3-mediated [3H]-E217G transport (left panel) and
MRP4-mediated [3H]-DHEAS transport (right panel) were measured in membrane vesicles from MRP3- or MRP4-overexpressing cells or the respective control cells in the
presence of 4 mM ATP or AMP. MRP-mediated ATP-dependent uptake was calculated, as described in Materials and Methods. Each point represents mean6 S.D. [n = 1 in
triplicate for time dependency (A); representative mean 6 S.D. data of two independent experiments performed in triplicate for concentration dependency (B)].
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between inhibition of MRP3 and MRP4 and the cholestatic potential of
drugs based on the putative role of these proteins as transporters that
protect hepatocytes from the accumulation of potentially toxic bile
acids.
A 96-well high-throughput membrane vesicle assay was developed to
measure MRP3 and MRP4 inhibition; high protein expression and trans-
port of the model substrates E217G and DHEAS were observed in MRP3
and MRP4 membrane vesicles, respectively. The Km values estimated for
MRP3 (9.1 mM) and MRP4 (3.5 mM) were consistent with previously
reported Km values of 17–43 mM for MRP3 (Zelcer et al., 2001; Akita
et al., 2002), and 2 mM for MRP4 (Zelcer et al., 2003a) (Fig. 1).
In the present study, a few compounds exhibited .100% inhibition of
MRP3 or MRP4, suggesting a more complex interaction with substrate
transport in membrane vesicles (e.g., inhibition of ATP-independent
transport processes, or allosteric interactions). Interestingly, many of these
compounds (e.g., troglitazone, sorafenib, rifampicin, ritonavir) are also
potent inhibitors of other transport proteins. In addition, a few drugs
stimulated MRP3 or MRP4 transport activity (,0% inhibition). Although
stimulation has been observed for other drug transporters such as MRP2
and organic anion transporting polypeptides (OATPs), the physiologic
consequences are not known. At least in our study, the compounds that
stimulated MRP transport do not appear to protect against hepatotoxicity;
a similar percentage of these compounds was present in the non-
cholestatic and cholestatic groups.
For BSEP non-inhibitors, a substantial association was detected
between the extent of inhibition of MRP4-mediated transport and
cholestatic potential, as follows: (1) for each 1% increase in MRP4
inhibition, the odds of the drug being cholestatic increased by 3.1%,
and (2) if the drug inhibited MRP4 by at least 21%, there was at least
a 50% chance of cholestasis (Fig. 3). Using the 21% inhibition as
a cutoff for classification of MRP4 inhibition, a strong enrichment of
MRP4 inhibitors among cholestatic compared with non-cholestatic
BSEP non-inhibitors was observed (62% versus 17%) (Table 2).
These findings highlight that screening for MRP4 inhibition may
reduce the false-negative rate (i.e., cholestatic compounds that do not
inhibit BSEP) observed when predicting cholestatic DILI based on in
vitro BSEP inhibition data.
As many BSEP inhibitors are not associated with cholestatic liver
injury, we hypothesized that knowledge about MRP3 and MRP4
inhibition also could provide additional information to discriminate
between cholestatic and non-cholestatic drugs in the group of BSEP
inhibitors. Interestingly, BSEP inhibitors tended to yield higher levels
of MRP4 inhibition (Fig. 2), and we observed that almost all BSEP
inhibitors also inhibited MRP4 (Table 2). Consequently, for BSEP
inhibitors, the extent of MRP4 inhibition did not provide additional
information as a predictor of cholestatic potential. Although there was
a slight, but not statistically significant, enrichment of MRP4 in-
hibitors among cholestatic compounds, these data suggest that MRP4
inhibition alone is unable to distinguish between cholestatic and non-
cholestatic drugs among BSEP inhibitors.
MRP3 inhibition (regardless of BSEP-inhibitor status) was not
predictive of cholestasis based on the present data. The importance of
MRP4 over MPR3 in cholestatic conditions is supported by studies
using knockout mice. Increased liver toxicity, decreased serum bile
Fig. 2. Inhibitory potency of non-cholestatic (n = 40) and cholestatic drugs (n = 48) on MRP3-(A) and MRP4-(B) mediated transport. Compounds were classified based on
cholestatic potential and further classified as BSEP non-inhibitors versus BSEP inhibitors using an IC50 cutoff of 135 mM based on taurocholate transport in BSEP membrane
vesicles. The Left panel indicates ATP-dependent E217G (MRP3) (A) and DHEAS (MRP4) (B) uptake measured in the presence of 100 mM compound or vehicle. Data are
presented as percent inhibition compared with vehicle-treated control; values show mean6 S.D. of three independent experiments. Compounds are ordered by the magnitude
of percent inhibition, and the order does not necessarily match for MRP3 and MRP4 inhibition. Pioglitazone, a cholestatic BSEP inhibitor, was omitted from the MRP3 figure
for presentation purposes (mean percent inhibition 2166% 6 66%). Right panel indicates box-and-whisker plots of percent MRP3 and MRP4 inhibition by type of liver
injury for BSEP non-inhibitors and BSEP inhibitors. The boxes show median (2), mean (+), and upper and lower quartiles. The whiskers indicate the trimmed range of
values defined by 1.5 times the interquartile range, whereas values outside the trimmed range are highlighted (d).
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TABLE 1.
Inhibitory effect of 88 compounds on MRP3-mediated E217G transport and MRP4-mediated DHEAS transport, and reported BSEP inhibition
Values in bold indicate that the compounds are defined as MRP3 and MRP4 inhibitors at a concentration of 100 mM based on a cutoff of 19% and 21% for inhibition of MRP3- and MRP4-mediated
transport to predict cholestatic potential, respectively.
Drug Pharmacology DILI Type DILI Severity
MRP3 % Inhibition MRP4 % Inhibition BSEP Inhibition






5-Fluorouracil Antineoplastic 2d 26 6 12 1 6 26 .135
Alprenolol Antihypertensive 2d 17 6 3 10 6 40 .135
Antipyrine Analgesic/Antipyretic 2 28 6 23 25 6 15 .135
Aspirin NSAID HCe 9 6 11 9 6 42 .135
Caffeine Stimulant 2d 3 6 10 5 6 9 .135
Chlorpheniramine Antihistamine 2d 0 6 7 20 6 10 .135
Clopamide Diuretic 2d 6 6 24 10 6 16 .135
Dexamethasone Antiinflammatory/
Immunosuppressant
2d 29 6 9 5 6 34 137.4 .135
Diphenhydramine Antihistamine 2d 7 6 2 31 6 9 .135
Doxorubicin Antineoplastic HCe 27 6 19 12 6 12 .135
Etoposide Antineoplastic HCe 107 6 7 33 6 21 .135
Fluorescein Diagnostic 2d 84 6 17 5 6 10 .135
Metoclopramide Antiemetic 2 f 3 6 21 212 6 22 .135
Nadolol Antianginal/Antihypertensive 2d 30 6 9 225 6 24 .135
Naloxone Opioid antagonist 2d 9 6 9 27 6 24 .135
Phenformin Antidiabetic 2d 15 6 9 20 6 50 .135
Probenecid Antigout agent HCg 65 6 13 8 6 28 564.8
Quinidine Antiarrhythmic HCe 55 6 4 77 6 8 .135
Tacrine Colinesterase inhibitor HCe 25 6 17 6 6 12 .1000 .135
Terbutaline Sympathicomimetic 2 f 22 6 11 20 6 8 .135
Theophylline Antiasthmatic 2g 13 6 19 4 6 8 .135
Timolol Antianginal/Antihypertensive 2d, f 16 6 18 12 6 13 .135
Triamterene Diuretic 2g 23 6 27 31 6 21 .135
Vinblastine Antineoplastic HCe 85 6 11 10 6 19 .135
Cholestatic BSEP Non-inhibitors
Bezafibrate Antilipemic Cg 2 6 31 41 6 6 231.7
Carbamazepine Antiepileptic Cg 222 6 45 23 6 14 .1000
Chloramphenicol Antibiotic Ce 22 6 20 6 6 25 .135
Chlorpromazine Antipsychotic Cg 77 6 12 84 6 4 147.6 .135
Chlorpropamide Antidiabetic Ce 15 6 15 212 6 44 .1000 .135
Cimetidine Histamine H2 antagonist C
e 0 6 16 0 6 13 .135
Desipramine Antidepressant Ce 38 6 27 27 6 9 .135
D-Penicillamine Antiinflammatory Cg 9 6 8 210 6 13 .1000
Famotidine Histamine H2 antagonist C
d 19 6 3 16 6 10 .1000 .135
Fluoxetine Antidepressant Cf 69 6 3 70 6 15 .135
Furosemide Diuretic Cd 29 6 14 109 6 20 .1000 .135
Haloperidol Antipsychotic Ce 36 6 10 34 6 32 .135
Ibuprofen NSAID Cg 21 6 33 39 6 15 598.6 .135
Maprotiline Antidepressant Cg 40 6 21 29 6 1 .135
Metformin Antidiabetic Cd BBW 23 6 14 26 6 33 .135
Nitrofurantoin Antibiotic Cg 27 6 11 101 6 11 .1000
Nortriptyline Antidepressant Ce 54 6 20 36 6 10 .135
Promethazine Antiemetic C (P.I.) 29 6 19 64 6 8 .135
Quinine Antimalarial Cg 7 6 17 41 6 21 .135
Ranitidine Histamine H2 antagonist C
e 7 6 5 10 6 10 .1000 .135
Sulfasalazine Antiinflammatory Cd 119 6 6 118 6 13 .135
Sulindac NSAID Ce 75 6 13 112 6 9 226 .135
Tamoxifen Antiestrogen Ce 120 6 14 102 6 7 .135
Tolbutamide Antidiabetic Ce 38 6 11 25 6 23 .1000 .135
Trimethoprim Antibiotic Ce 15 6 17 9 6 17 .135
Verapamil Antiarrhythmic Ce 77 6 11 44 6 7.4 .135
Non-cholestatic BSEP Inhibitors
Alpidem Anxiolytic HCb Withdrawn 55 6 13 47 6 15 9.2
Benzbromarone Antigout agent HCd Withdrawn 121 6 8 111 6 4 17.5
Buspirone Anxiolytic 2d 29 6 25 13 6 6 104.5
Clobetasol propionate Corticosteroid 2d 83 6 10 101 6 23 8.5
Finasteride 5a-Reductase inhibitor 2d 22 6 5 49 6 8 28.2
Flupirtine Nonopioid analgesic agent HCh 31 6 17 11 6 13 35.5
Glafenine NSAID HCe 59 6 20 105 6 9 22.3
Lopinavir Antiretroviral HCd 105 6 20 76 6 11 17.3
Mibefradil Antihypertensive 2d 95 6 5 91 6 18 ,135
Oxybutynin Antispasmodic 2d 51 6 10 67 6 19 27.4
Praziquantel Anthelmintic 2b 252 6 11 59 6 16 96.8
Primaquine Antiprotozoal HCe 35 6 13 11 6 23 32.7
(continued )
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acid concentrations, and elevated liver concentrations of specific bile
acids were reported after bile duct ligation in Mrp4 knockout mice, but
not in Mrp3 knockout mice compared with wild-type mice (Belinsky
et al., 2005; Mennone et al., 2006; Zelcer et al., 2006).
Unfortunately, preclinical models currently fail to reliably predict
hepatotoxicity. This may be due to: 1) differences in bile acid
disposition/composition between species; 2) disparate intracellular
concentrations of hepatotoxic drugs due to species differences in
binding, metabolism, and/or excretion; and/or 3) species-dependent
interactions of compounds with drug transporters, either as a substrate
or an inhibitor. An accurate method to identify compounds with
hepatotoxic potential early in development is urgently needed. Testing
the inhibitory potential of compounds for interactions with human
hepatic bile acid transporters using appropriate in vitro systems could
help prioritize compounds and identify molecules that would require
further investigations (e.g., bile acid profiling, special screens for liver
toxicity during phase II/III trials). Limitations of membrane vesicle
assays include the lack of metabolic activity, the absence of
subcellular organelles that may play an important role in trafficking,
sequestration and excretion of compounds and derived metabolites
within hepatocytes, and lack of interaction with other transport
proteins compared with the in vivo situation. Polarized hepatocyte
systems may provide more useful information. Of course, these in
vitro systems in isolation cannot predict critical information about the
pharmacokinetic properties of the compound, or the contribution of
hepatic clearance to overall elimination. Use of metabolites in the
membrane vesicle screening approach might improve predictability of
cholestatic liver injury, although human-specific metabolites are not
always available or even known. Especially during early development,
when information on metabolites might not be readily available, use of
S9 fractions in combination with the membrane vesicle assay could
bypass this limitation.
In this study, we used E217G and DHEAS as surrogate model
substrates to assess the inhibition potential toward MRP3 and MRP4,
respectively. Consistent with previous findings by Morgan et al.
(2013), bile acids could not be used as reliable assay substrates to
accurately predict MRP inhibitors. It is unknown whether bile acids
would be more sensitive substrates to predict cholestasis. Neverthe-
less, our data demonstrate that the MRP4 inhibition potential of
a compound toward the surrogate substrate can improve prediction of
the cholestatic potential.
Selection of the appropriate concentration for transport inhibition
studies is the subject of much debate. Theoretically, the unbound
hepatic cytosolic inhibitor concentration would be the relevant
concentration to select for these studies. As discussed in the recently
published International Transporter Consortium white paper (Chu
et al., 2013), intracellular unbound concentrations may be similar to,
or orders of magnitude higher than, plasma concentrations, depending
TABLE 1.—Continued
Drug Pharmacology DILI Type DILI Severity
MRP3 % Inhibition MRP4 % Inhibition BSEP Inhibition





Sorafenib Tyrosine kinase inhibitor HCd 114 6 5 121 6 17 8
Taxol Antineoplastic HCf 57 6 38 14 6 26 15
Tolcapone COMT inhibitor HCi BBW 101 6 20 113 6 17 119.6 34.5
Valinomycin Antibiotic 24 6 19 65 6 13 1.6
Cholestatic BSEP Inhibitors
Acitretin Antipsoriatic retinoid Cj BBW 4 6 26 33 6 14 18.2
Clozapine Antipsychotic Ce 30 6 16 25 6 5 126.1 .135
Cyclosporin A Immunosuppressant Ce 106 6 14 23 6 12 0.5 0.9
Dicloxacillin Antibiotic Cg 90 6 9 41 6 18 69.7 ,135
Erythromycin Estolate Antibiotic Cg 2 6 25 79 6 6 4.1 13
Fenofibrate Antilipemic Ce 5 6 8 39 6 3 15.3
Fluvastatin Antilipemic Cd 93 6 11 62 6 2 36.1
Glyburide Antidiabetic Ce 98 6 4 93 6 1 5.3 6.1
Indinavir Antiretroviral Cd 75 6 7 15 6 24 21.2
Indomethacin NSAID Ce 64 6 2 111 6 18 42
Nifedipine Antianginal, antihypertensive Cg 32 6 14 46 6 6 30.7
Nitrendipine Antihypertensive Cd 45 6 11 93 6 11 ,135
19-Norethindrone Contraceptive Cd 18 6 14 33 6 19 ,135
Omeprazole Proton pump inhibitor Cd 12 6 16 21 6 17 ,135
Pioglitazone Antidiabetic Ck 2116 6 48 34 6 16 0.3 0.3
Rifampicin Antibiotic Cg 93 6 15 60 6 14 11.3 25.3
Rifamycin SV Antibiotic Cg 111 6 6 75 6 9 6.3
Ritonavir Antiretroviral Cd 112 6 6 72 6 3 2.2
Rosiglitazone Antidiabetic Ck 244 6 9 88 6 10 6.4 4.4
Simvastatin Antilipemic Cg 122 6 5 111 6 8 24.7
Ticlopidine Antiplatelet Cg 245 6 34 35 6 12 74
Troglitazone Antidiabetic Cl Withdrawn 121 6 4 105 6 5 2.7 5.9
BBW, black box warning; C, cholestatic; COMT, catechol-O-methyl transferase; HC, hepatocellular; NSAID, nonsteroidal anti-inflammatory drug; P.I., package insert;2, no reports of liver injury.
aControl is defined as uptake in presence of 1% DMSO, no inhibitor (100% transport).
bDawson et al., 2012.





hPuls et al., 2011.
iMayoral et al. 1999.
jKreiss et al., 2002.
kFloyd et al., 2009.
lKaplowitz and DeLeve, 2007.
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on the intrinsic hepatic uptake and elimination clearance values. The
concentration selected for investigation in the present study (100 mM)
was in the same range as recently published data showing a correlation
between BSEP inhibition and the cholestatic potential of drugs in
which IC50 cutoff values of ;130 mM or even 300 mM were used to
predict cholestatic versus non-cholestatic drugs, despite generally low
unbound plasma concentrations (Morgan et al., 2010; Dawson et al.,
2012). Further work is needed to measure relevant hepatocyte con-
centrations of drugs and their metabolites, and evaluate the association of
unbound intracellular concentrations with the occurrence of cholestatic
DILI. This approach also may help identify compounds that are BSEP
inhibitors in vitro but are not cholestatic in vivo.
Factors other than MRP3, MRP4, and BSEP inhibition that may
improve the prediction of liver injury also were examined in the present
study. Robust statistical regression analyses suggested that the extent of
hepatic metabolism was not associated with the risk of cholestatic liver
injury (Supplemental Table 2). Consistent with our findings, Lammert
et al. observed no statistically significant relationship between the extent
of metabolism and drugs that caused jaundice, which often is associated
with cholestasis. In contrast, these authors did detect a relationship
between the extent of hepatic metabolism and some types of hepatic
injury such as liver failure or fatal DILI (Lammert et al., 2010).
However, the intracellular concentration of metabolite(s) that inhibits
bile acid transport rather than the extent of overall metabolism is more
likely the important factor associated with liver injury.
Similarly, the primary route of excretion was not associated with
risk of cholestatic liver injury (Supplemental Table 3). This is contrary
to the results of a previous study showing that jaundice was associated
with biliary excretion (Lammert et al., 2010). Interestingly, statistical
analyses revealed an apparent association between biliary excretion
and BSEP inhibition (data not shown). This is surprising because
BSEP has been reported to have limited ability to transport drugs; only
pravastatin and vinblastine have been identified as substrates of human
or rodent BSEP (Lecureur et al., 2000; Hirano et al., 2005). These
results suggest that close proximity to the canalicular membrane is
important to exert BSEP inhibition in vivo, or that there is a strong
overlap between substrates of canalicular drug transporters such as
MRP2 or BCRP, and BSEP inhibitors.
Daily dose is an important factor for development of DILI; drugs with
daily doses .50 mg demonstrate an increased risk of causing liver
failure (Lammert et al., 2008; Lucena et al., 2009). Our study did not
detect an association between the type of liver injury (non-cholestatic
no-liver injury versus cholestatic) and the maximal or average daily
dose or Cmax,u (Fig. 4; Supplemental Table 4). Notably, higher median
Cmax,u values were observed for cholestatic drugs that were not BSEP or
MRP4 inhibitors compared with cholestatic drugs that were BSEP
or MRP4 inhibitors, respectively. Cholestatic drugs that are BSEP or
MRP4 non-inhibitors may have different physicochemical properties
that also influence pharmacokinetic parameters.
While the present work was under review, Morgan et al. (2013)
published new findings supporting the hypothesis that the risk of DILI
may be even greater if the compound inhibits one or more of the other
hepatic bile acid transporters (MRP2, MRP3, and/or MRP4) in
addition to BSEP. They recommend that if the compound is a BSEP
inhibitor, the inhibitory potency on MRP2, MRP3, and MRP4 also
should be evaluated to improve the correlation with liver injury com-
pared with inhibition of BSEP alone. Adding to these findings, our
data emphasize that even among BSEP non-inhibitors, MRP4 in-
hibition is associated with an increased risk of cholestatic potential.
Thus, screening for MRP4 inhibition can reduce the rate of false
negatives (i.e., cholestatic compounds that do not inhibit BSEP).
In conclusion, this work highlights that inhibition of MRP4,
a basolateral bile acid transporter, is a risk factor for the development
of cholestatic DILI. This result is consistent with the hypothesis that
inhibition of bile acid transporters contributes to the development of
cholestatic DILI. Although inhibition of hepatic bile acid transport is
a susceptibility factor for the development of liver injury, other
Fig. 3. Logistic regression curves for estimated probability of cholestatic potential based on the percent MRP4 inhibition among BSEP non-inhibitors (A) and BSEP
inhibitors (B). The bold curves show the estimated probability of cholestasis, and the shaded areas represent 95% confidence intervals. The symbols denote the observed
percent MRP4 inhibition values for cholestatic (values = 1.00) and non-cholestatic (values = 0.00) drugs. The inset shows the estimated odds ratios with 95% confidence
intervals for different MRP4 inhibition values (e.g., a compound exhibiting 35% MRP4 inhibition has 2.9-fold greater odds of being cholestatic).
TABLE 2.
Association of MRP4 inhibition and type of liver injury
Compounds were defined as MRP4 inhibitors at a concentration of 100 mM based on a cutoff
of 21% for inhibition of MRP4-mediated transport to predict cholestatic potential. x2 test P values
are shown.
MRP4 Inhibition
BSEP Non-inhibitors (n = 50)
Cholestatic Non-cholestatic P value
MRP4 non-inhibitors 10 20
0.0016
MRP4 inhibitor 16 4
BSEP Inhibitors (n = 38)
Cholestatic Non-cholestatic P value
MRP4 non-inhibitors 1 4
0.14
MRP4 inhibitor 21 12
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environmental, genetic, immunologic, as well as drug-specific factors
may influence the overall risk for a patient to develop DILI. The
present data strongly suggest that, in addition to BSEP inhibition,
evaluating the interaction potential of drug candidates with human
MRP4 could aid in identifying compounds with reduced liability of
DILI at a much earlier stage in drug development.
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